DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
August 17 2021 - 3:30PM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB:DGNOF), a leader in early detection of critical health
issues, announces that the 2021 annual general and special meeting
of shareholders (the “Meeting”) will be held on September 10th,
2021, at 10 a.m.
Purposes of the Meeting
- To receive the annual report of management, the audited
consolidated financial statements of the Corporation for the
financial year ended March 31, 2021 and the independent auditor’s
report thereon;
- To elect the directors of the Corporation;
- To reappoint Raymond Chabot Grant Thornton, LLP, as independent
auditor of the Corporation for the ensuing year and to authorize
the directors to fix its remuneration;
- To approve by ordinary resolution the amendment to the
Corporation’s existing stock option plan to increase the maximum
number of common shares that may be issued pursuant thereto, from
9,000,000 to 10,200,000, as approved by the Board of directors on
August 10th, 2021; and
- To transact such other business as may properly come before the
Meeting or any adjournment thereof.
The Corporation is strongly recommending all
shareholders to vote by proxy in advance of the Meeting.
Attendance / participation at the
Meeting Due to COVID-19 sanitary measures, Registered
Shareholders and Non-registered Holders (as defined in the
Management Information Circular available on www.sedar.com) who do
not intend to vote at the Meeting are kindly asked to participate
via videoconferencing using this link;
https://meet.google.com/bss-ebhp-pmm.
Only Registered Shareholders and duly appointed
proxyholders who intend to vote at the Meeting will be able to
attend the Meeting in person at the Corporation’s head office
located at 7005 Taschereau Blvd, suite 265, Brossard, Qc.
About DIAGNOS DIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of CARA (Computer Assisted Retina
Analysis). CARA is a tele-ophthalmology platform that integrates
with existing equipment (hardware and software) and processes at
the point of care. CARA’s image enhancement algorithms make
standard retinal images sharper, clearer and easier to read. CARA
is accessible securely over the internet, and is compatible with
all recognized image formats and brands of fundus cameras, and is
EMR compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. Marc-André Massue, CFO and Secretary
DIAGNOS Inc.
Tel: 450-678-8882 ext. 235
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024